Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. - Wikidata - awgldk - TriplyDB

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

http://www.wikidata.org/entity/Q37249366

about

The role of the ALK receptor in cancer biology Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance Translating cancer genomes and transcriptomes for precision oncology The distinctive nature of adenocarcinoma of the lung Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application Genetic instability in the tumor microenvironment: a new look at an old neighbor Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Controlling the Master: Chromatin Dynamics at the MYC Promoter Integrate Developmental Signaling The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Molecular pathways and therapeutic targets in lung cancer The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Emerging treatment for advanced lung cancer with EGFR mutation.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations Clinical potential of gene mutations in lung cancer.Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor.Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis

P2860

Q26738384-E3F601B0-6210-4A8D-B779-A5CB84B9F308 Q26741318-9AF73068-8BBF-498D-B786-618EDB91B5EC Q26745427-42268C7B-DA09-4301-848B-22EE50AE0C29 Q26749110-05CE1458-B412-4EB1-BC36-102CC775C370 Q26775379-F24DEA2A-353D-4B7F-87DB-26FB1904F433 Q26777081-0661F96D-2CA0-4510-B783-CD6819075920 Q26781159-EE4CC78C-D0C8-4D3C-B09D-1B1CBFF38CD3 Q26795555-DB1F9F7E-7320-4A65-B2BB-80DD1DD3A4A5 Q26795556-C04007F3-2970-4025-8454-7DB8666389D1 Q26801374-99C51FF2-F58E-415C-9D3F-06FED33CAEEA Q26823788-77B76B3D-1C30-4B7B-AC8C-CA045C7EEC53 Q27004161-9D7B28A1-9C65-4D3C-A570-AF352E6D3F0D Q27014117-31EABC67-F9FC-428A-9958-0E25695ACC43 Q27853015-836F6ACD-092D-4C53-81F8-C4C87C4C918C Q27853138-7FBE20A9-DB63-48B3-8617-8F25BCBAEAF5 Q27853317-CCF1327F-3449-404D-8399-43AF6E402957 Q28649561-1D2FC6C8-FFEB-4415-B028-E04BFEE610D1 Q30278774-9B4C967A-E3DA-4509-A71D-6EC29547B00A Q30850656-2D424C01-C167-42F6-B57F-00A33CD6E69C Q33567383-0D51F986-D13A-4C3F-9E6A-D2795FD96B33 Q33608508-6B8683F0-126A-4349-A63B-2B5A2A9F6D18 Q33618747-867DBC23-957E-4C42-98A0-EB63756F5BFD Q33688872-B694485E-B2F2-4C8B-AFA6-CB5C589BE338 Q33755975-01C93E3E-3867-4FB0-BE3D-158C939F5792 Q33865965-D80CE2D1-8A94-443F-9438-87C8774578E8 Q33873274-6A0DC7FF-260D-4E50-81A7-C576E6DADF6A Q34431889-06F1D9EB-20A2-4DB0-A7A6-A92F38C46F92 Q34483953-649C285E-6566-4B77-A338-8F51C832519E Q34564071-D9BF0703-CAE2-4EFD-8342-612C2782D1FF Q34650994-4E97FDC3-1359-42A1-92A7-29C58E618BB4 Q35256622-EA043E23-53B6-4B84-BBD7-35E4337A63F4 Q35751883-1E7A573B-86CB-4CB5-8026-9CEAD5DDBC18 Q35858617-0D4DB424-7D10-401F-B2AF-B822C7837828 Q35979767-9CE816E4-2DA8-4FBE-8DC0-0DE15D833429 Q36077810-1C3A0B42-52AA-401A-8B93-72206ADAA50F Q36316009-BE4C5E93-9B8A-43E1-AFDA-DC6FC7691488 Q36414239-5B16F8B1-B3EB-4F1C-B23F-58C4CB475B5D Q36558400-B2864EE9-7836-4DB1-ABA0-86F1F642469E Q36710172-C935C496-696F-43F1-ACFE-45098371CD79 Q36847104-479BA004-81C9-4D44-8AE9-BB4D57766607

P2860

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

http://www.wikidata.org/entity/Q37249366

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging paradigms in the deve ...... ase inhibitors in lung cancer.

@en

Emerging paradigms in the deve ...... ase inhibitors in lung cancer.

@nl

type

label

Emerging paradigms in the deve ...... ase inhibitors in lung cancer.

@en

Emerging paradigms in the deve ...... ase inhibitors in lung cancer.

@nl

prefLabel

Emerging paradigms in the deve ...... ase inhibitors in lung cancer.

@en

Emerging paradigms in the deve ...... ase inhibitors in lung cancer.

@nl

P1433

Q37249366-8BF6E594-0704-4BFC-AB80-FB985CE47C87

P1476

Q37249366-A24A32D9-E889-41B5-8D52-3E64D6818F20

P2093

Q37249366-9CD245C1-7109-4D87-AF70-2B14FBB6C267

Q37249366-BC090863-255E-4DE9-8DE0-B8CD3683E4CB

P2860

Q37249366-003A41F7-DB23-4755-9139-54A9535986A6

Q37249366-00C24CB9-B103-4439-9217-8CD334F75712

Q37249366-02858BA8-DC25-4E2E-BA9C-BFDB5F9373AF

Q37249366-041D9448-4421-4519-B5AF-641EC0296A13

Q37249366-07FC6418-E993-444E-9F82-0B02A0ACB8BA

Q37249366-08DBA9F7-5525-4400-BF38-20DBE4E60A72

Q37249366-0EC6E3CA-8086-4F5F-9DEB-D0B38AFFDCBB

Q37249366-12258745-5FD4-4AA2-93D3-7B0BB0B0C228

Q37249366-1E1585D1-538D-42FD-B8B1-31718C77AF85

Q37249366-1F8410FF-2F12-4BCA-9DBA-25BC970E6C0C

P304

Q37249366-96502729-B889-4E82-935B-3EB1A1856FB9

P31

Q37249366-61AF39C5-91C8-4435-B62C-0C1AB28ED059

P356

Q37249366-7EF56D20-C3BC-4CDE-89B0-D7F7596317E2

P407

Q37249366-E917305A-9165-408A-B364-3EA119AD71AC

P433

Q37249366-59ECDE1C-D612-49B9-AC77-EDD9A004AC41

P478

Q37249366-9DA0DC97-BDAD-4158-8E9D-E4085E329BF3

P577

Q37249366-1A5E01A2-0A2A-4D46-8E11-51D479F1C5FE

P698

Q37249366-ED773740-3A49-4885-B79F-E3653CF4F024

P932

Q37249366-2FEA8862-235B-404B-8D7B-7F42AC49F929

P356

JCO.2012.45.2029

P1433

Journal of Clinical Oncology

P1476

Emerging paradigms in the deve ...... ase inhibitors in lung cancer.

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Justin F Gainor

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

P304

3987-3996

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.45.2029

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24101047

http://www.w3.org/2001/XMLSchema#string

P932

3805932

http://www.w3.org/2001/XMLSchema#string